Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2025 | Story André Damons | Photo Supplied
Prof Wynand Goosen
Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards.

Being nominated for a ‘Science Oscar’ is exciting and validates nominees’ efforts, particularly in a field as challenging and essential as infectious diseases, for which they are recognised at the highest level. 

This is according to Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State (UFS). He was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards for his landmark discovery of Mycobacterium bovis infection in humans in South Africa – the first confirmed cases in the country. 

Prof Goosen, who previously won the NSTF-South32 Emerging Researcher Award, says the nomination is a powerful affirmation of the impact that focused, interdisciplinary research can have. It reflects not only his personal commitment but also the dedication of a talented and hard-working team. “I am honoured and humbled to be nominated. It is also a testament to the support and vision of UFS, particularly as we position ourselves as leaders in One Health research in South Africa,” he says. 

 

Focus of research 

He was nominated by Prof Vasu Reddy, UFS Deputy Vice-Chancellor: Research and Internationalisation, and Prof Paul Oberholster, Dean for the Faculty of Natural and Agricultural Sciences (NAS) at the UFS, and Prof Nico Gey van Pittius and Prof Elmi Muller from Stellenbosch University (US). The NSTF Awards, known as the ‘Science Oscars’of SA, honour, reward, celebrate, profile and promote outstanding contributions to science, engineering and technology (SET) and innovation in South Africa.

“The nomination,” Prof Goosen continues, “recognises our work in the field of zoonotic tuberculosis (TB) and other emerging infectious diseases at the human-animal-environment interface. Our research focuses on the molecular detection and characterisation of pathogenic mycobacteria in wildlife, livestock, and human populations, with the aim of informing better surveillance, diagnostics, and control strategies — particularly in high-risk ecosystems. This includes novel applications in wildlife TB surveillance and understanding the transmission dynamics between animals and people.”

 

Establishing a Kovsie One Health Research Unit

This research is critically important as South Africa continues to face a high burden of tuberculosis, including zoonotic TB, which often goes under-detected in rural and wildlife-rich areas. Understanding how these pathogens circulate between humans, animals, and the environment, explains Prof Goosen, is essential for effective disease control and to mitigate future pandemics. This work directly supports national health priorities, informs policy, and contributes to global strategies for One Health.

Prof Goosen and the team are in the process of laying the groundwork for the establishment of a Kovsie One Health Research Unit, which will serve as a collaborative platform for research spanning human, animal, and environmental health. One of their key projects involves expanding TB and AMR surveillance in wildlife-livestock-human interfaces, using cutting-edge diagnostics and genomic tools. They are also initiating partnerships with industry and international institutions to address emerging zoonoses and environmental pathogens in a transdisciplinary manner.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept